Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Frech

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
Best Practice & Research. Clinical Rheumatology|July 4, 2021
Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS)Henrik Pettersson, Helene Alexanderson, Janet L Poole, et al.
Rheumatology (Oxford, England)|July 11, 2025
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosisHana Sabanovic, John D Pauling, Murray Baron, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Rheumatology (Oxford, England)|October 20, 2019
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritisCynthia Aranow, John Cush, Marcy B Bolster, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
Best Practice & Research. Clinical Rheumatology|July 4, 2021
Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS)Henrik Pettersson, Helene Alexanderson, Janet L Poole, et al.
Rheumatology (Oxford, England)|July 11, 2025
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosisHana Sabanovic, John D Pauling, Murray Baron, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
Journal of Scleroderma and Related Disorders|March 26, 2019
An Interim Report of the Scleroderma Clinical Trials Consortium Working GroupsMurray Baron, Bashar Kahaleh, Elana J Bernstein, et al.
Rheumatology (Oxford, England)|October 20, 2019
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritisCynthia Aranow, John Cush, Marcy B Bolster, et al.
Journal of Scleroderma and Related Disorders|May 19, 2025
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'Corrado Campochiaro, Yossra A Suliman, Dilia Giuggioli, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Pageof 6